Contemporary management of phyllodes tumours of the breast: recommendations from the UK Association of Breast Surgery - Takeaways - MDSpire

Contemporary management of phyllodes tumours of the breast: recommendations from the UK Association of Breast Surgery

  • By

  • Mai K Bishr

  • Alex Humphreys

  • Mahbubl Ahmed

  • Karina Cox

  • Adam Hughes

  • Jen Isherwood

  • Sarah E Pinder

  • Dionysios D Remoundos

  • Elinor Sawyer

  • Muhammad S Tamimy

  • Lisa Whisker

  • August 23, 2025

  • 0 min

Share

  • 1

    Phyllodes tumours account for about 0.5% of all breast tumours, primarily affecting women in their 40s and 50s.

  • 2

    These tumours are classified into benign, borderline, and malignant categories, influencing clinical management and prognosis.

  • 3

    Management of phyllodes tumours varies significantly, with overtreatment of benign lesions noted in less experienced centers.

  • 4

    Guidelines for phyllodes tumour management have been developed by a multidisciplinary panel and endorsed by several professional organizations.

  • 5

    Clinical suspicion for phyllodes tumours should be raised in cases of growing fibroadenomas or lesions with specific imaging characteristics.

Original Source(s)

Contemporary management of phyllodes tumours of the breast: recommendations from the UK Association of Breast Surgery

  • by Mai K Bishr, Alex Humphreys, Mahbubl Ahmed, Karina Cox, Adam Hughes, Jen Isherwood, Sarah E Pinder, Dionysios D Remoundos, Elinor Sawyer, Muhammad S Tamimy, Lisa Whisker

  • August 23, 2025

Related Content

Trimodal Treatment Approaches for Inflammatory Breast Cancer

Oral and Head and Neck Cancers Rising: What You Need to Know

Most people know that tobacco use is a major risk factor for oral and head and neck cancers. Some even understand that excessive alcohol consumption also ups the odds.

  • by

  • April 6, 2026

  • 7 min
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in operable breast cancer patients with hormone receptor-positive, HER2-negative